American Heart Association Congratulates Califf on Confirmation as FDA Commissioner

February 24, 2016 Categories: Advocacy News

Washington, D.C., February 24, 2016 – American Heart Association CEO Nancy Brown issued the following comments today on the Senate’s confirmation of Robert M. Califf, M.D. as the next commissioner of the Food and Drug Administration (FDA):

“We could not imagine a better person than Dr. Califf to lead the FDA. His dynamic résumé makes him a triple threat when it comes to combating public health problems in this country.

Dr. Califf has a patient-centric approach, his regulatory experience gives him a valuable perspective on medical product development, and he has a proven track record of leading groundbreaking clinical and translational research initiatives. He also brings to the position the leadership skills he gained as founding director of the Duke Clinical Research Institute and as current Deputy Commissioner of Medical Products and Tobacco.

It’s these experiences, combined with his commitment to improving the health of our nation that make him a perfect fit for this role. Americans will greatly benefit from his expertise and his unique ability to work with all stakeholders.

Dr. Califf understands the science of the drugs and devices used in trials, but can also be critical of study design. He will be effective at finding new ways to advance the development and delivery of innovative medical products – without compromising their safety and efficacy. He will also be adept at building on the FDA’s work to curb tobacco use and ensure the safety of foods.

We have been fortunate enough to have Dr. Califf as a member of our association and have witnessed first-hand his strong commitment to the fight against heart disease and stroke. We hope we can count on his continued interest in the issues surrounding cardiovascular diseases.

Throughout his already distinguished career in medicine and clinical research, Dr. Califf has advanced science and medical care, and we are confident that he will only continue to do so in this role at the FDA. We look forward to working with the FDA under his leadership to promote public health initiatives and build healthier lives, free of heart disease and stroke.”


Media Contact: Abbey Dively (202) 785-7905